Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Bio-Techne Corporation
TECH
NASDAQ·Healthcare·Biotechnology·Mkt cap $11.1B
$70.83
▼ -0.25%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$43.20 - $72.16
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 33.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive product portfolio
- Advanced proprietary technologies
- Strong brand reputation in scientific research
- Global distribution network
Bear Case
2 risks
- Average volatility.
- Premium valuation to Biotech & Therapeutics peers
Growth
Stable outlook
Increasing investment in life science research
Value
Premium valuation to Biotech & Therapeutics peers
Momentum
Hot
+33.6% over 3m
Quality
Excellent
Excellent business quality
Dividend
Token
0.45% yield
Smart-money signal
Who's buying TECH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 5, 2026
MAY 6, 2026
Reported EPS of $0.53 vs $0.55 consensus (-3.6% surprise). Revenue of $311.4M vs $316.1M expected (-1.5%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-3.6%
Next: May 5, 2026
Revenue trend · last 8Q
—
—
—
+9%
+4%
+4%
-1%
-0%
Q3 24
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
$303.4M
$306.1M
$289.5M
$297.0M
$316.2M
$317.0M
$286.6M
$295.9M
Margins · last 8Q
Gross
64.6%
Operating
18.4%
Profit
12.8%
Wall Street consensus
10 analysts · 20% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
20%
Hold
80%
Sell
0%
Median Price Target
$50.00
▼ -29.4% vs $70.83
Latest: Benchmark · Jun 30, 2026
4 analysts covering